Sun Pharma Advanced Research Company (SPARC) is all set to launch its dry powder inhaler in the country in the next two months. The company has developed a Dry Powder Inhaler (DPI) compliant to US Food and Drug Administration (USFDA) and European requirements.
The pre-metered, 60 dose, inhalation activated device for the administration of combination of inhaled steroids and bronchodilator drugs delivers a uniform dose over a range of patient effort. However, the company has not disclosed the possible price range of the product.
The company, which recently launched its Timolol OD eye drops in the country, is also looking to market the products in emerging markets, including China.
SPARC is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).
| Company Name | CMP |
|---|---|
| Syngene Internation. | 477.50 |
| Indegene | 534.20 |
| CMS Info Systems | 290.30 |
| JITF Infralogistics | 294.30 |
| Sagility | 41.62 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: